A System of Rhinomanometry in the Clinical Evaluation of Nasal Decongestants
William E. Dressler, Todd M. Myers, A. S. Rankell, S. J. London, C. E. Poetsch
Abstract
William E. Dressler, Todd M. Myers, A. S. Rankell, S. J. London, C. E. Poetsch
Abstract
The utility of an anterior rhinomanometric method for the assessment of decongestant drug activity is illustrated with representative clinical data. Controlled studies employing topical nasal spray, nasal inhaler, and oral syrup formulations were conducted under single- or double-blind conditions in patients with allergic or coryzal rhinitis. The method provided an objective means to distinguish active from placebo (vehicle) treatments and to discriminate differences in decongestant activity between two active formulations. Furthermore, objectively determined increases in nasal patency paralleled the patients' subject-ve perception of improved airflow. In conclusion, this rhinomanometric methodology provided objective confirmation of drug activity with orally-administered, inhaled, and topically-applied decongestant drug formulations.
OpenAlex reports 20 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The utility of an anterior rhinomanometric method for the assessment of decongestant drug activity is illustrated with representative clinical data. Controlled studies employing topical nasal spray, nasal inhaler, and oral syrup formulations were conducted under single- or double-blind conditions in patients with allergic or coryzal rhinitis. The method provided an objective means to distinguish active from placebo (vehicle) treatments and to discriminate differences in decongestant activity between two active formulations. Furthermore, objectively determined increases in nasal patency paralleled the patients' subject-ve perception of improved airflow. In conclusion, this rhinomanometric methodology provided objective confirmation of drug activity with orally-administered, inhaled, and topically-applied decongestant drug formulations.
Key concepts: Decongestant, Rhinomanometry, Nasal decongestant, Medicine, Inhaler, Placebo, Nasal spray, Anesthesia